|
|
Volumn 46, Issue 10, 2010, Pages 1770-1772
|
|
The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer
a
a
a
a
a
a
a
a
|
|
Author keywords
Chemotherapy; Docetaxel; Prostate cancer
|
|
Indexed keywords
DOCETAXEL;
ESTRAMUSTINE;
PROSTATE SPECIFIC ANTIGEN;
ANTINEOPLASTIC AGENT;
TAXOID;
ADULT;
AGED;
ANEMIA;
ARTICLE;
ASTHENIA;
CANCER CHEMOTHERAPY;
CANCER GROWTH;
CASTRATION REFRACTORY PROSTATE CANCER;
CLINICAL ARTICLE;
CONCENTRATION (PARAMETERS);
CONSENSUS;
DRUG EFFICACY;
DRUG FATALITY;
DRUG SAFETY;
DRUG TOLERABILITY;
DRUG WITHDRAWAL;
FEBRILE NEUTROPENIA;
HUMAN;
MALE;
METASTASIS;
NEUTROPENIA;
OVERALL SURVIVAL;
PRIORITY JOURNAL;
PROGRESSION FREE SURVIVAL;
PROSTATE CANCER;
RETREATMENT;
TREATMENT RESPONSE;
BLOOD;
DISEASE FREE SURVIVAL;
DRUG ADMINISTRATION;
METABOLISM;
MIDDLE AGED;
PROSTATIC NEOPLASMS;
TIME;
TREATMENT OUTCOME;
AGED;
ANTINEOPLASTIC AGENTS;
DISEASE-FREE SURVIVAL;
DRUG ADMINISTRATION SCHEDULE;
HUMANS;
MALE;
MIDDLE AGED;
PROSTATE-SPECIFIC ANTIGEN;
PROSTATIC NEOPLASMS;
TAXOIDS;
TIME FACTORS;
TREATMENT OUTCOME;
|
|
EID: 77953289240
PISSN: 09598049
EISSN: None
Source Type: Journal
DOI: 10.1016/j.ejca.2010.04.010 Document Type: Article |
|
Times cited : (84)
|
|
References (8)
|
